Innovative cell therapies for cancer

Pioneering
CD30 Targeting
in Cell Therapy

Late stage clinical program with
RMAT and PRIME Designation

Learn About our CD30 CAR-T technology

Differentiated
Allogeneic Platform

Based on Virus specific T cells
and CD30 CAR

Learn More

Experienced
Leadership Team

Explore

Building in-house
Manufacturing Facility

Explore

Our Partners

Press Releases & Events